Wuxi AppTec UK Ltd is a dynamic, privately held limited liability company established on January 17th, 2011 under the regulatory number 07495313. Currently operating as an active entity, WuXi AppTec’s UK division focuses primarily on providing comprehensive sourcing and supply chain solutions within the global pharmaceutical and biotechnology industries. The company operates with a significant international presence, leveraging strategic partnerships to deliver value across multiple continents. As a subsidiary of Wuxi Pharmaceutical Co., Ltd., a publicly traded Chinese enterprise, WuXi AppTec UK plays a critical role in facilitating the development and commercialization of innovative medicines globally. Their services encompass drug discovery support, preclinical research, clinical trials management, manufacturing solutions, and regulatory consulting – all underpinned by significant investment from investors including China National Financial Group (CNFG) and various private equity firms. WuXi AppTec UK’s core business model centers on connecting pharmaceutical companies with a broad network of suppliers and partners, offering specialized expertise in complex drug development processes. The company's size estimates place it as a key contributor to the UK’s biotechnology sector, actively supporting both domestic and international research efforts. The company employs a significant number of skilled workers, demonstrating its commitment to operational excellence within the industry.

Wuxi AppTec UK Ltd is a dynamic, privately held limited liability company established on January 17th, 2011 under the regulatory number 07495313. Currently operating as an active entity, WuXi AppTec’s UK division focuses primarily on providing comprehensive sourcing and supply chain solutions within the global pharmaceutical and biotechnology industries. The company operates with a significant international presence, leveraging strategic partnerships to deliver value across multiple continents. As a subsidiary of Wuxi Pharmaceutical Co., Ltd., a publicly traded Chinese enterprise, WuXi AppTec UK plays a critical role in facilitating the development and commercialization of innovative medicines globally. Their services encompass drug discovery support, preclinical research, clinical trials management, manufacturing solutions, and regulatory consulting – all underpinned by significant investment from investors including China National Financial Group (CNFG) and various private equity firms. WuXi AppTec UK’s core business model centers on connecting pharmaceutical companies with a broad network of suppliers and partners, offering specialized expertise in complex drug development processes. The company's size estimates place it as a key contributor to the UK’s biotechnology sector, actively supporting both domestic and international research efforts. The company employs a significant number of skilled workers, demonstrating its commitment to operational excellence within the industry.